Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16959550 | 0.84 | ERN1 (0.44) | ERN1APLNRALDH1A1CYP1A2CYP1A1 | |
| SCHEMBL630627 | 0.82 | ERN1 (0.43) | ERN1APLNRALDH1A1KDM4EKMT2A | |
| SCHEMBL16953704 | 0.81 | ERN1 (0.39) | ERN1APLNRALDH1A1KDM4EKMT2A | |
| SCHEMBL20767542 | 0.77 | LTA4H (0.51) | ALDH1A1 | |
| SCHEMBL9065566 | 0.77 | CYP1A2 (0.52) | ERN1ALDH1A1KDM4EKMT2ACYP1A2 | |
| SCHEMBL2060421 | 0.77 | HTR2A (0.47) | APLNRCYP1A2HTR2ACYP2A6HSD17B10 | |
| SCHEMBL30567454 | 0.77 | CYP1A2 (0.52) | ERN1ALDH1A1KDM4EKMT2ACYP1A2 | |
| SCHEMBL825091 | 0.76 | ERN1 (0.43) | ERN1ALDH1A1KDM4EKMT2ACYP1A2 | |
| SCHEMBL630820 | 0.76 | ABCB11 (0.36) | ERN1ALDH1A1KDM4EKMT2ACYP1A2 | |
| SCHEMBL630819 | 0.76 | ABCB11 (0.36) | ERN1ALDH1A1KDM4EKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| EP-2074102-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008043567-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043567-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | ERN1 3196/4885APLNR 2463/4885ALDH1A1 2690/4885 |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | ESR1, GPER1, ESR2 | ERN1 289/4885APLNR 415/4885ALDH1A1 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.